| Literature DB >> 29529595 |
Beata Znorko1, Dariusz Pawlak2, Ewa Oksztulska-Kolanek1, Tomasz Domaniewski1, Anna Pryczynicz3, Alicja Roszczenko4, Joanna Rogalska4, Paweł Lipowicz5, Michał Doroszko6, Malgorzata Michalina Brzoska4, Krystyna Pawlak7.
Abstract
Osteoprotegerin (OPG), receptor activator of NF-κB ligand (RANKL), and parathyroid hormone (PTH) play a central role in the regulation of bone turnover in chronic kidney disease (CKD), but their influence on bone mineral density (BMD) and strength remains unclear, particularly in children. We studied the clinical significance of OPG and RANKL in relation to PTH, femur weight, BMD, and bone biomechanical properties in growing rats after one month (CKD-1) and three months (CKD-3) of surgically-induced mild CKD. Gene expression of parathyroid hormone 1 receptor (PTH1R) and activating transcription factor 4 (ATF4), major regulators of anabolic PTH response in bone, was also determined. Serum PTH and bone PTH1R/ATF4 expression was elevated in CKD-3 compared with other groups, and it positively correlated with femur weight, BMD, and the biomechanical properties of the femoral diaphysis reflecting cortical bone strength. In contrast, bone RANKL/OPG ratios were decreased in CKD-3 rats compared with other groups, and they were inversely correlated with PTH and the other abovementioned bone parameters. However, the PTH-PTH1R-ATF4 axis exerted an unfavorable effect on the biomechanical properties of the femoral neck. In conclusion, this study showed for the first time an inverse association between serum PTH and the bone RANKL/OPG system in growing rats with mild CKD. A decrease in the RANKL/OPG ratio, associated with PTH-dependent activation of the anabolic PTH1R/ATF4 pathway, seems to be responsible for the unexpected, beneficial effect of PTH on cortical bone accrual and strength. Simultaneously, impaired biomechanical properties of the femoral neck were observed, making this bone site more susceptible to fractures.Entities:
Keywords: Growing rats; Mild chronic kidney disease; PTH1R/ATF4 pathway; Parathyroid hormone; RANKL/OPG system
Mesh:
Substances:
Year: 2018 PMID: 29529595 DOI: 10.1016/j.cyto.2018.03.002
Source DB: PubMed Journal: Cytokine ISSN: 1043-4666 Impact factor: 3.861